Green Thumb Industries on Massachusetts Repeal: “Cannabis Demand Won’t Disappear, but the $330M Tax Base Will”

Massachusetts could become the first U.S. state to reverse adult-use cannabis legalization, putting hundreds of millions of dollars in annual tax revenue and years of private investment at risk.

Green Thumb Industries, which has operated in Massachusetts since 2018, faces the possibility of losing access to a recreational market where it has invested in cultivation facilities, manufacturing operations, retail dispensaries, workforce development, and local supply chains. The November 3 vote on Question 8 could force the company and other licensed operators to reconsider their investments in the state.

“Capital follows regulatory certainty,” David Bodurtha, Massachusetts Commercial General Manager for Green Thumb’s RISE Dispensaries, told IgniteIt in an exclusive interview.

“That would signal to lenders and investors, in Massachusetts and beyond, that a voter-approved, licensed and taxed business can be undone after years of investment,” he said.

If approved, Question 8 would end legal adult-use cannabis sales on January 1, 2028, while preserving the state’s medical cannabis program.

Massachusetts voters approved adult-use legalization in 2016. A decade later, they are being asked whether to dismantle the commercial market that followed.

$330 Million in Cannabis Taxes at Stake

The financial consequences could extend well beyond cannabis operators.

According to figures Bodurtha cited from the Secretary of the Commonwealth’s 2026 Information for Voters, adult-use cannabis retail taxes generated approximately $280 million in state revenue and $50 million in local revenue during fiscal year 2025.

The Massachusetts Department of Revenue puts fiscal year 2026 collections at approximately $336 million, he added.

“The $330 million is what adult-use sales have already generated,” Bodurtha explained.

Massachusetts currently applies a 6.25% sales tax and a 10.75% excise tax to adult-use cannabis purchases, with municipalities authorized to impose an additional local option tax of up to 3%.

Those collections represent only part of the industry’s broader fiscal contribution.

“These figures also capture only a small portion of the tax revenue cannabis businesses generate. They count taxes collected on retail sales, but not cannabis licensing and regulatory fees, host community impact fees, or ordinary business, payroll, and income taxes,” Bodurtha said.

The company is not predicting that cannabis consumption would disappear if legal sales were prohibited. Instead, it argues that spending would shift toward channels that do not generate the same tax revenue.

“The assumption is simple—revenue exists only while sales happen in licensed adult-use stores. Medical cannabis isn’t taxed, so spending that moves to the medical market or to unregulated sellers produces no tax revenue,” he said.

“We aren’t assuming demand disappears. We’re saying the tax base does.”

The $330 million figure represents historical annual tax collections, rather than a forecast of the precise revenue Massachusetts would lose if Question 8 passes.

What Happens to Green Thumb’s Massachusetts Operations?

Green Thumb currently operates three recreational RISE Dispensaries in Chelsea, Dracut and Maynard, along with the medical-only Affinity West Springfield dispensary.

Its Massachusetts operations also support cultivation, manufacturing and a network of suppliers and service providers.

“Through RISE Dispensaries, we’ve created hundreds of jobs in Massachusetts across cultivation, manufacturing, retail and support suppliers, service providers and small businesses across the regulated industry,” Bodurtha said.

But Green Thumb is not yet willing to quantify the potential financial damage to its business.

“We won’t speculate on specific financial outcomes before the vote, and our employees would hear from us first. Question 8 puts Massachusetts jobs, businesses, and local economies at risk.”

The proposed law would provide operators with a transition period before adult-use sales end in January 2028.

It would also allow licensed recreational cannabis businesses to apply through an expedited process to become medical dispensaries and sell their remaining adult-use inventory to medical operators.

Those provisions offer a possible route for restructuring, but they do not guarantee that existing businesses could maintain their current scale.

“The measure does allow licensed adult-use businesses to apply on an expedited basis to become medical dispensaries and to sell their remaining adult-use inventory to medical dispensaries,” Bodurtha said.

“We would evaluate every option, and our employees would hear from us first.”

Why Medical Cannabis Cannot Replace Adult-Use Sales

Although Question 8 would preserve Massachusetts’ medical cannabis program, Green Thumb does not consider that market an adequate replacement for recreational sales.

The distinction matters for operators evaluating whether existing retail stores, cultivation facilities and manufacturing infrastructure could remain economically viable after a repeal.

“Medical patients remain a top priority for us, and the medical program will continue regardless of the November 3 outcome,” Bodurtha said.

“The measure would allow adult-use licensees to convert to medical operations, and we would evaluate that option carefully. However, the medical program serves a far smaller customer base and isn’t a replacement for the adult-use market.”

That smaller customer base could limit the ability of converted businesses to support operations originally developed for recreational demand.

Bodurtha did not provide estimates of potential store closures, facility reductions, or employment losses.

The Illicit Market and the Fate of Established Cannabis Brands

Green Thumb also argues that ending legal sales would not necessarily reduce cannabis consumption.

Instead, the company believes Question 8 could redirect consumers toward unregulated suppliers.

“Ending legal sales does not eliminate demand. It risks pushing consumers back to the illicit market,” Bodurtha said.

“It would remove the regulated marketplace while leaving demand intact, creating a greater incentive for consumers to turn to illicit sources. The medical program cannot simply fill that gap because it requires certification and is built to serve patients.”

Licensed cannabis retailers operate under requirements involving age verification, laboratory testing, child-resistant packaging, seed-to-sale tracking and inspections.

Those requirements distinguish regulated products from cannabis sold outside the legal market.

For Green Thumb, the proposed repeal would also affect the availability of its established consumer brands.

Bodurtha identified RYTHM flower and vapes, Dogwalkers pre-rolls, Beboe edibles and Incredibles edibles among the products that would disappear from licensed adult-use shelves if Question 8 passes.

He also cited &Shine, Dr. Solomon’s and Good Green as brands that Massachusetts recreational consumers would lose access to through licensed adult-use stores.

“People will keep consuming cannabis. Question 8 determines whether adults in Massachusetts can continue purchasing cannabis from licensed, tested businesses or whether they will turn to unregulated, illicit market vendors,” he said.

The company’s position assumes that a meaningful portion of existing adult-use demand would migrate to illicit sellers rather than disappear or transition into the medical program. Bodurtha did not provide a quantitative estimate of how consumers would respond.

A Regulatory Precedent for Cannabis Investors Nationwide

Beyond the immediate impact on Massachusetts operators, Question 8 could introduce another consideration for cannabis investors: the possibility that a previously legalized market can be reversed.

For companies financing cultivation facilities, dispensary networks, and manufacturing operations, regulatory stability is an important part of evaluating long-term investment.

A repeal would demonstrate that businesses operating under voter-approved legalization can face a fundamental change in their addressable market after committing capital.

“Massachusetts voters legalized adult-use in 2016, and Question 8 would make it the first state to reverse legalization,” Bodurtha said.

“We won’t speculate about specific investment decisions, but I’d expect anyone underwriting a cannabis business to take the precedent seriously.”

His comments raise a question for lenders and equity investors evaluating cannabis assets in other states: How should they price the risk that legalization itself might be reversed?

Green Thumb has not disclosed whether Question 8 has already affected its financing, investment plans, or capital allocation decisions.

As Massachusetts weighs the future of its regulated cannabis market, questions about taxation, regulatory certainty, and access to capital are becoming increasingly important for operators and investors nationwide. Join industry executives, policymakers and financial leaders at IgniteIt’s Capital & Policy Summit in Washington, D.C., on November 18, where the conversation will focus on the policy decisions, investment risks and opportunities shaping the next chapter of the U.S. cannabis industry.

Green Thumb’s Plan if Question 8 Passes

With the November 3 election approaching, Green Thumb is publicly opposing the proposed repeal.

Bodurtha argues that voters may misunderstand what the measure would accomplish.

“Many people hear ‘repeal’ and assume it means less cannabis. In reality, it means less regulation,” he said.

Under the proposal, adults could continue possessing and gifting limited quantities of cannabis, but the licensed recreational supply chain and home cultivation rights would be eliminated.

Green Thumb supports a No vote, which would preserve the current adult-use framework.

If voters approve the measure, the company says its immediate priority would be communicating with employees before evaluating the future of its operations.

“If it passes, our people will be our priority. Leadership would address our Massachusetts team the day after the vote and meet with store teams within a week,” Bodurtha said.

“We would then evaluate our facilities and the medical conversion process while working with the Cannabis Control Commission and the Legislature to manage the transition.”

For now, the company is withholding specific financial projections and restructuring decisions until voters determine the future of Massachusetts’ recreational cannabis market.

But the broader issue extends beyond one operator or one state. A successful repeal would establish a new regulatory precedent for an industry already navigating federal restrictions, financing challenges, and uneven state-level market conditions.

For investors, the Massachusetts vote could become a test of how durable state cannabis legalization really is.